Multiple applications of flurbiprofen and chlorhexidine chips in patients with chronic periodontitis: a randomized, double blind, parallel, 2‐arms clinical trial

Abstract

AimThe aim of the present randomized, double blind, parallel, 2-arm clinical study was to examine the safety and efficacy of frequent applications of chlorhexidine chip (CHX) and flurbiprofen chip (FBP) in patients with chronic periodontitis.MethodsSixty patients were randomized into CHX and FBP groups. Following OHI and scaling and root planing (SRP), baseline pocket depth (PD) measurements, gingival recession and bleeding on probing (BOP) were performed and repeated at week 4 and 8. The assigned chip was placed at weeks 0, 1, 2, 3, 5, 7.ResultsMean PD reduction in the CHX group was 2.08 mm (7.17 to 5.09, p < 0.0001). Mean PD reduction in the FBP group was 2.27 mm (6.72 to 4.45, p < 0.0001). Ninety-seven percentage and 95% of these sites exhibited PD reduction ≥1 mm, while 38% and 34% of the sites exhibited PD ≥3 mm (FBP and CHX, respectively). Clinical attachment level gain (1.66 and 1.95 mm, respectively) was statistically significant (p < 0.0001). Baseline BOP dropped from 98% and 100% to 24% and 30% for the CHX and FBP groups, respectively (p < 0.0001).ConclusionFrequent applications of CHX and FBP chips resulted in a significant improvement in the periodontal condition in these sites. Furthermore studies will be required to compare this new treatment regimen to SRP or SRP with single chip application.

Adjunctive Effects of A Piscean Collagen-Based Controlled-Release Chlorhexidine Chip in the Treatment of Chronic Periodontitis: A Clinical and Microbiological Study

“…Mean PPD reduction from baseline to week 11 visit for the SRP plus CHX group was 1.9 ± 0.32 mm similar to the results obtained by Kondreddy K et al, [30] where he noted a mean reduction in probing pocket depth between 0 and 90 th day of 1.6±0.5 mm and 1.26+1.19 mm as seen by Grover V et al, [17]. Mean PPD reduction of 2.08 mm was noted in a similar study after 8 weeks and could be attributed to the repeated placement of CHX chips as opposed to the single time placement in the present study [31]. An additional PPD reduction of 0.8 mm was obtained in the SRP plus CHX group as compared to the SRP group at 11 weeks.…”

Treatment of peri‐implantitis using multiple applications of chlorhexidine chips: a double‐blind, randomized multi‐centre clinical trial

“…More recently, we have reported (Machtei et al. ) on the clinical response to a similar intensive protocol of chlorhexidine chips placement around teeth: Mean PD reduction was incredibly similar (2.09 mm) compared with that around implants in this study (2.13 mm); In contrary, CAL gain in this study (2.18 mm) was much greater than what we have achieved around teeth (1.66 mm). This phenomenon would require further research as it may lend some clues to the less favourable response to therapy often reported with dental implants (Lang & Berglundh ).…”

“…Recently (Machtei et al 2011), we have been able to demonstrate that frequent application of biodegradable matrix containing chlorhexidine (PerioChip ® ; Dexcel Pharma, Or-Akiva, Israel) in patients with chronic periodontitis with PD ! 5 mm resulted in a sizeable improvement in mean PD (2.1 mm) and gain in CAL (1.7 mm).…”

Effects of a single topical doxycycline administration adjunctive to mechanical debridement in patients with persistent/recurrent periodontitis but acceptable oral hygiene during supportive periodontal therapy

“…Attempts to address this issue have included repeated administration of the antimicrobial (Machtei et al. ). In this trial, however, repeated USI was performed at sites with PPD ≥4 mm at the 3‐, 6‐ and 9‐month follow‐up for both the test and control groups; the short duration of the additive benefit of SRD needs to be interpreted in this context.…”